<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-147354</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Comparative study on the usefulness of antibacterial prophylaxis with levofloxacin in patients submitted to hematopoietic stem cell transplantation</dc:title>
<dc:description xml:lang="en">Background: Bacterial infection remains a frequent complication in patients receiving a hematopoietic stem cell transplantation (HSCT). However, the impact of the antibacterial prophylaxis mortality in these patients is controversial. Patients and methods: Retrospective comparison of 2 consecutive groups of patients undergoing HSCT receiving (n = 132) or not (n = 107) antibacterial prophylaxis with levofloxacin. Results: 41% of patients receiving prophylaxis with levofloxacin had microbiologically documented infection (MDI) with bacteremia, compared with 40% of those not receiving levofloxacin. The frequency of gram-negative bacteremia was 11 and 38%, the resistance to levofloxacin was 39 and 14%, and the mortality was 8 and 7%, respectively. Conclusions; In our experience, the use of levofloxacin as prophylaxis in HSCT was associated with a lower frequency of gram-negative bacteremia but was not associated with a decreased rate of MDI and did not influence their outcome. In contrast, there was an increase in quinolone resistance in patients treated with levofloxacin (AU</dc:description>
<dc:creator>Ribera Santasusana, Josep María</dc:creator>
<dc:creator>Fernandez Sojo, Jesús</dc:creator>
<dc:creator>Morgades, Mireia</dc:creator>
<dc:creator>Batlle Massana, Montserrat</dc:creator>
<dc:creator>Vives Polo, Susana</dc:creator>
<dc:creator>Quesada, María Dolores</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Fundamento: La infección bacteriana continúa siendo una complicación frecuente en pacientes receptores de un trasplante de progenitores hematopoyéticos (TPH). No obstante, el impacto de la profilaxis antibacteriana en la mortalidad de estos pacientes es controvertido. Pacientes y métodos: Comparación retrospectiva de 2 grupos consecutivos de receptores de TPH según recibieran (n = 132) o no (n = 107) profilaxis antibacteriana con levofloxacino. Resultados: En el 41% de los procedimientos de TPH en los que se administró profilaxis con levofloxacino se constató infección microbiológicamente documentada (IMD) con bacteriemia, frente a un 40% de los que no recibieron levofloxacino. La frecuencia de bacteriemia por bacilos gramnegativos fue del 11 y del 38%, la resistencia a levofloxacino fue del 39 y del 14%, y hubo un 8 y 7% de muertes, respectivamente. Conclusiones: En nuestra experiencia, el uso de levofloxacino se asoció a una menor frecuencia de bacteriemia por microorganismos gramnegativos, pero no se asoció a disminución en la tasa de IMD ni influyó en su evolución. En cambio, hubo un aumento de la resistencia a quinolonas en los pacientes tratados con levofloxacino (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);146(1): 16-19, ene. 2016. tab</dc:source>
<dc:identifier>ibc-147354</dc:identifier>
<dc:title xml:lang="es">Estudio comparativo sobre la utilidad de la profilaxis antibacteriana con levofloxacino en pacientes receptores de un trasplante de progenitores hematopoyéticos</dc:title>
<dc:subject>^d30037^s22045</dc:subject>
<dc:subject>^d29103^s22038</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d22164^s22021</dc:subject>
<dc:subject>^d29103^s22021</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d30241^s22057</dc:subject>
<dc:subject>^d30241^s22012</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:subject>^d32857^s22045</dc:subject>
<dc:subject>^d30077^s22021</dc:subject>
<dc:subject>^d30077^s22001</dc:subject>
<dc:subject>^d7414^s22057</dc:subject>
<dc:subject>^d55251^s22073</dc:subject>
<dc:subject>^d30241^s22054</dc:subject>
<dc:type>article</dc:type>
<dc:date>201601</dc:date>
</metadata>
</record>
</ibecs-document>
